{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T02:52:03Z","timestamp":1777171923628,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,6]],"date-time":"2014-04-06T00:00:00Z","timestamp":1396742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s10549-014-2910-1","type":"journal-article","created":{"date-parts":[[2014,4,5]],"date-time":"2014-04-05T05:58:45Z","timestamp":1396677525000},"page":"245-254","source":"Crossref","is-referenced-by-count":42,"title":["Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy"],"prefix":"10.1007","volume":"145","author":[{"given":"Daniel L.","family":"Hertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Jack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison A.","family":"Motsinger-Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Drobish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Scott","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Claire","family":"Dees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,6]]},"reference":[{"issue":"24","key":"2910_CR1","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1200\/JCO.2004.02.122","volume":"22","author":"V Di\u00e9ras","year":"2004","unstructured":"Di\u00e9ras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L et al (2004) Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22(24):4958\u20134965","journal-title":"J Clin Oncol"},{"issue":"11","key":"2910_CR2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/djn151","volume":"100","author":"M Martin","year":"2008","unstructured":"Martin M, Rodriguez-Lescure \u00c3, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100(11):805\u2013814","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2910_CR3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976\u2013983","journal-title":"J Clin Oncol"},{"issue":"1","key":"2910_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/WNL.47.1.115","volume":"47","author":"RJ Freilich","year":"1996","unstructured":"Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology. 47(1):115\u2013118","journal-title":"Neurology."},{"issue":"10","key":"2910_CR5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00001813-200311000-00003","volume":"14","author":"S Mielke","year":"2003","unstructured":"Mielke S, Mross K, Gerds TA, Schmidt A, Wasch R, Berger DP et al (2003) Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3\u00a0h. Anticancer Drugs 14(10):785\u2013792","journal-title":"Anticancer Drugs"},{"issue":"8","key":"2910_CR6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0959-8049(94)90459-6","volume":"30","author":"JMA Gerven van","year":"1994","unstructured":"van Gerven JMA, Moll JWB, van den Bent MJ, Bontenbal M, van der Burg MEL, Verweij J et al (1994) Paclitaxel (taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30(8):1074\u20131077","journal-title":"Eur J Cancer"},{"issue":"13","key":"2910_CR7","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","volume":"11","author":"S Mielke","year":"2005","unstructured":"Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D et al (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843\u20134850","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2910_CR8","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-12-3786","volume":"19","author":"AJ Graan de","year":"2013","unstructured":"de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B et al (2013) CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 19(12):3316\u20133324","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2910_CR9","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.13.90","volume":"14","author":"DL Hertz","year":"2013","unstructured":"Hertz DL (2013) Germline pharmacogenetics of paclitaxel for cancer treatment. Pharmacogenomics 14(9):1065\u20131084","journal-title":"Pharmacogenomics"},{"issue":"21","key":"2910_CR10","first-page":"5543","volume":"54","author":"A Rahman","year":"1994","unstructured":"Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6{alpha}-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54(21):5543\u20135546","journal-title":"Cancer Res"},{"issue":"1","key":"2910_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04165.x","volume":"74","author":"DL Hertz","year":"2012","unstructured":"Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K et al (2012) Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br J Clin Pharmacol 74(1):197\u2013200","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2910_CR12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7):597\u2013607","journal-title":"Pharmacogenetics"},{"issue":"2","key":"2910_CR13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/tpj.2010.19","volume":"11","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F et al (2011) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 11(2):113\u2013120","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"2910_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/tpj.2010.13","volume":"11","author":"S Leskela","year":"2011","unstructured":"Leskela S, Jara C, Leandro-Garcia L, Martinez A, Garcia-Donas J, Hernando S et al (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11(2):121\u2013129","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"2910_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-012-2054-0","volume":"134","author":"DL Hertz","year":"2012","unstructured":"Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA et al (2012) CYP2C8*3 predicts benefit\/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134(1):401\u2013410","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2910_CR16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","volume":"24","author":"DL Hertz","year":"2013","unstructured":"Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL et al (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24(6):1472\u20131478","journal-title":"Ann Oncol"},{"issue":"25","key":"2910_CR17","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2011.39.8446","volume":"30","author":"BP Schneider","year":"2012","unstructured":"Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V et al (2012) Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 30(25):3051\u20133057","journal-title":"J Clin Oncol"},{"issue":"5","key":"2910_CR18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JOP.2012.000863","volume":"9","author":"RM Speck","year":"2013","unstructured":"Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG et al (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):234\u2013240","journal-title":"J Oncol Pract"},{"issue":"1","key":"2910_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/pgs.09.154","volume":"11","author":"TM Sissung","year":"2010","unstructured":"Sissung TM, English BC, Venzon D, Figg WD, Deeken JF (2010) Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1):89\u2013103","journal-title":"Pharmacogenomics"},{"key":"2910_CR20","unstructured":"Common terminology criteria for adverse events (CTCAE) version 4.0 (2010) US Department of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"issue":"6968","key":"2910_CR21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","volume":"426","author":"The international HapMap project","year":"2003","unstructured":"The international HapMap project (2003) Nature 426(6968):789\u2013796","journal-title":"Nature"},{"issue":"4","key":"2910_CR22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/FPC.0b013e3283510a51","volume":"22","author":"YJ He","year":"2012","unstructured":"He YJ, Shapero MH, McLeod HL (2012) Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. Pharmacogenet Genomics 22(4):322\u2013324","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"2910_CR23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2133\/dmpk.23.165","volume":"23","author":"R Singh","year":"2008","unstructured":"Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE (2008) Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23(3):165\u2013174","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"2910_CR24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/tpj.2009.57","volume":"10","author":"JF Deeken","year":"2010","unstructured":"Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K et al (2010) A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J 10(3):191\u2013199","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"2910_CR25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","volume":"38","author":"AL Price","year":"2006","unstructured":"Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8):904\u2013909","journal-title":"Nat Genet"},{"issue":"2","key":"2910_CR26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/genetics\/155.2.945","volume":"155","author":"JK Pritchard","year":"2000","unstructured":"Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155(2):945\u2013959","journal-title":"Genetics"},{"key":"2910_CR27","author":"I Iacobucci","year":"2012","unstructured":"Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S et al (2012) Profiling of drug-metabolizing enzymes\/transporters in CD33+ acute myeloid leukemia patients treated with gemtuzumab-ozogamicin and fludarabine, cytarabine and idarubicin. Pharmacogenomics J. doi: 10.1038\/tpj.2012.13","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"2910_CR28","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00280-012-1872-4","volume":"69","author":"T Uchiyama","year":"2012","unstructured":"Uchiyama T, Kanno H, Ishitani K, Fujii H, Ohta H, Matsui H et al (2012) An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel. Cancer Chemother Pharmacol 69(6):1617\u20131624","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2910_CR29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/cbt.12.9.17781","volume":"12","author":"MT Martino Di","year":"2011","unstructured":"Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Saveria Rotundo M, Ciliberto D et al (2011) Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. Cancer Biol Ther 12(9):780\u2013787","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"2910_CR30","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8):4106\u20134112","journal-title":"Blood"},{"issue":"19","key":"2910_CR31","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19):2553\u20132560","journal-title":"Circulation"},{"issue":"1","key":"2910_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","volume":"22","author":"LB Ramsey","year":"2012","unstructured":"Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P et al (2012) Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 22(1):1\u20138","journal-title":"Genome Res"},{"issue":"18","key":"2910_CR33","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-13-0487","volume":"19","author":"AJ Graan de","year":"2013","unstructured":"de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ et al (2013) A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res 19(18):5210\u20135217","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2910_CR34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1073\/pnas.97.2.817","volume":"97","author":"J Klucken","year":"2000","unstructured":"Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G et al (2000) ABCG1 (ABC8), the human homolog of the drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 97(2):817\u2013822","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2910_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1194\/jlr.M700364-JLR200","volume":"49","author":"PT Tarr","year":"2008","unstructured":"Tarr PT, Edwards PA (2008) ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J Lipid Res 49(1):169\u2013182","journal-title":"J Lipid Res"},{"issue":"1","key":"2910_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jcp.1041230104","volume":"123","author":"WE Rainey","year":"1985","unstructured":"Rainey WE, Kramer RE, Mason JI, Shay JW (1985) The effects of taxol, a microtubule-stabilizing drug, on steroidogenic cells. J Cell Physiol 123(1):17\u201324","journal-title":"J Cell Physiol"},{"issue":"1","key":"2910_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.pneurobio.2010.04.009","volume":"92","author":"V Schaeffer","year":"2010","unstructured":"Schaeffer V, Meyer L, Patte-Mensah C, Mensah-Nyagan A (2010) Progress in dorsal root ganglion neurosteroidogenic activity: basic evidence and pathophysiological correlation. Prog Neurobiol 92(1):33\u201341","journal-title":"Prog Neurobiol"},{"issue":"5216","key":"2910_CR38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.7770777","volume":"268","author":"HL Koenig","year":"1995","unstructured":"Koenig HL, Schumacher M, Ferzaz B, Thi AN, Ressouches A, Guennoun R et al (1995) Progesterone synthesis and myelin formation by Schwann cells. Science 268(5216):1500\u20131503","journal-title":"Science"},{"issue":"1","key":"2910_CR39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.expneurol.2009.04.017","volume":"218","author":"IH Yang","year":"2009","unstructured":"Yang IH, Siddique R, Hosmane S, Thakor N, Hoke A (2009) Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration. Exp Neurol 218(1):124\u2013128","journal-title":"Exp Neurol"},{"issue":"7","key":"2910_CR40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archneur.1994.00540190110024","volume":"51","author":"Z Sahenk","year":"1994","unstructured":"Sahenk Z, Barohn R, New P, Mendell JR (1994) Taxol neuropathy: electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51(7):726\u2013729","journal-title":"Arch Neurol"},{"issue":"1","key":"2910_CR41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1529-8027.2009.00204.x","volume":"14","author":"I Roglio","year":"2009","unstructured":"Roglio I, Bianchi R, Camozzi F, Carozzi V, Cervellini I, Crippa D et al (2009) Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst 14(1):36\u201344","journal-title":"J Peripher Nerv Syst"},{"issue":"17","key":"2910_CR42","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.ejca.2006.06.017","volume":"42","author":"TM Sissung","year":"2006","unstructured":"Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A et al (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17):2893\u20132896","journal-title":"Eur J Cancer"},{"issue":"18","key":"2910_CR43","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/1078-0432.CCR-12-1590","volume":"18","author":"RM Baldwin","year":"2012","unstructured":"Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C et al (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18(18):5099\u20135109","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2910_CR44","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10549-011-1671-3","volume":"130","author":"L Sucheston","year":"2011","unstructured":"Sucheston L, Zhao H, Yao S, Zirpoli G, Liu S, Barlow W et al (2011) Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130(3):993\u20131002","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"2910_CR45","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-12-1221","volume":"18","author":"LJ Leandro-Garcia","year":"2012","unstructured":"Leandro-Garcia LJ, Leskela S, Jara Sanchez C, Green H, Avall Lundqvist E, Wheeler HE et al (2012) Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res 18(16):4441\u20134448","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl 3","key":"2910_CR46","first-page":"1","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (taxol). Semin Oncol 20(4 Suppl 3):1\u201315","journal-title":"Semin Oncol"},{"issue":"1\u20132","key":"2910_CR47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jns.2011.11.009","volume":"315","author":"Y Anziska","year":"2012","unstructured":"Anziska Y, Helzner EP, Crystal H, Glesby MJ, Plankey M, Weber K et al (2012) The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci 315(1\u20132):129\u2013132","journal-title":"J Neurol Sci"},{"issue":"1","key":"2910_CR48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1464-5491.2011.03379.x","volume":"29","author":"LH Soderstrom","year":"2012","unstructured":"Soderstrom LH, Johnson SP, Diaz VA, Mainous AG (2012) Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001 to 2004 NHANES. Diabetic Med 29(1):50\u201355","journal-title":"Diabetic Med"},{"issue":"6","key":"2910_CR49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/pgs.11.17","volume":"12","author":"MW Roederer","year":"2011","unstructured":"Roederer MW, Sanchez-Giron F, Kalideen K, Kudzi W, McLeod HL, Zhang W et al (2011) Pharmacogenetics and rational drug use around the world. Pharmacogenomics 12(6):897\u2013905","journal-title":"Pharmacogenomics"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2910-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2910-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:07:06Z","timestamp":1648771626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2910-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,6]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2910-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,6]]}}}